UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 53

Sortiert nach

Chemically Defined Antibody– and Small Molecule–Drug Conjugates for in Vivo Tumor Targeting Applications: A Comparative Analysis

Journal of the American Chemical Society, 2018-02, Vol.140 (5), p.1617-1621

2018

Link zum Volltext

Verfügbarkeit prüfen

Versatile protein recognition by the encoded display of multiple chemical elements on a constant macrocyclic scaffold

Nature chemistry, 2018-04, Vol.10 (4), p.441

2018

Link zum Volltext

Verfügbarkeit prüfen

Enhanced Therapeutic Activity of Non-Internalizing Small-Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX in Combination with Targeted Interleukin-2

Clinical cancer research, 2018-08, Vol.24 (15), p.3656-3667

2018

Link zum Volltext

Verfügbarkeit prüfen

An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications

Proceedings of the National Academy of Sciences - PNAS, 2021-04, Vol.118 (16), p.1

2021

Link zum Volltext

Verfügbarkeit prüfen

Protease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody–Drug Conjugates

Bioconjugate chemistry, 2017-07, Vol.28 (7), p.1826-1833

2017

Link zum Volltext

Verfügbarkeit prüfen

Stereo- and regiodefined DNA-encoded chemical libraries enable efficient tumour-targeting applications

Nature chemistry, 2021-06, Vol.13 (6), p.540

2021

Link zum Volltext

Verfügbarkeit prüfen

An Attenuated Targeted-TNF Localizes to Tumors In Vivo and Regains Activity at the Site of Disease

International journal of molecular sciences, 2021-09, Vol.22 (18), p.10020

2021

Link zum Volltext

Verfügbarkeit prüfen

Targeted Delivery of Cytotoxic Drugs: Challenges, Opportunities and New Developments

Chimia, 2017-10, Vol.71 (10), p.712

2017

Link zum Volltext

Verfügbarkeit prüfen

Ex vivo mass spectrometry-based biodistribution analysis of an antibody-Resiquimod conjugate bearing a protease-cleavable and acid-labile linker

Frontiers in pharmacology, 2023-12, Vol.14, p.1320524-1320524

2023

Link zum Volltext

Verfügbarkeit prüfen

Automated Radiosynthesis, Preliminary In Vitro/In Vivo Characterization of OncoFAP-Based Radiopharmaceuticals for Cancer Imaging and Therapy

Pharmaceuticals (Basel, Switzerland), 2022-08, Vol.15 (8), p.958

2022

Link zum Volltext

Verfügbarkeit prüfen

Sortase-Mediated Site-Specific Modification of Interleukin‑2 for the Generation of a Tumor-Targeting Acetazolamide–Cytokine Conjugate

ACS omega, 2020-10, Vol.5 (40), p.26077-26083

2020

Link zum Volltext

Verfügbarkeit prüfen

Deep Learning Approach for the Discovery of Tumor-Targeting Small Organic Ligands from DNA-Encoded Chemical Libraries

ACS omega, 2023-07, Vol.8 (28), p.25090-25100

2023

Link zum Volltext

Verfügbarkeit prüfen

In Vivo Antitumor Activity of a Novel Acetazolamide–Cryptophycin Conjugate for the Treatment of Renal Cell Carcinomas

ACS omega, 2018-11, Vol.3 (11), p.14726-14731

2018

Link zum Volltext

Verfügbarkeit prüfen

Acetazolamide Serves as Selective Delivery Vehicle for Dipeptide-Linked Drugs to Renal Cell Carcinoma

Molecular cancer therapeutics, 2016-12, Vol.15 (12), p.2926-2935

2016

Link zum Volltext

Verfügbarkeit prüfen

Linker stability influences the anti-tumor activity of acetazolamide-drug conjugates for the therapy of renal cell carcinoma

Journal of controlled release, 2017-01, Vol.246, p.39-45

2017

Link zum Volltext

Verfügbarkeit prüfen

In Vivo Antitumor Activity of a Novel Acetazolamide–Cryptophycin Conjugate for the Treatment of Renal Cell Carcinoma

ACS omega, 2018-12, Vol.3 (12), p.16743-16743

2018

Link zum Volltext

Verfügbarkeit prüfen

A Dimeric FAP-Targeting Small-Molecule Radioconjugate with High and Prolonged Tumor Uptake

Journal of Nuclear Medicine, 2022-12, Vol.63 (12), p.1852-1858

2022

Link zum Volltext

Verfügbarkeit prüfen

Mass Spectrometry-Based Method for the Determination of the Biodistribution of Tumor-Targeting Small Molecule–Metal Conjugates

Analytical chemistry (Washington), 2022-08, Vol.94 (30), p.10715-10721

2022

Link zum Volltext

Verfügbarkeit prüfen

Targeted interleukin-2 enhances the in vivo anti-cancer activity of Pluvicto

European journal of nuclear medicine and molecular imaging, 2024-04

2024

Link zum Volltext

Verfügbarkeit prüfen

Response to: GCP III is not the “off-target” for urea-based PSMA-ligands

European journal of nuclear medicine and molecular imaging, 2023-08, Vol.50 (10), p.2947-2949

2023

Link zum Volltext

Verfügbarkeit prüfen

In vivo activation of FAP-cleavable small molecule-drug conjugates for the targeted delivery of camptothecins and tubulin poisons to the tumor microenvironment

Journal of controlled release, 2024-03, Vol.367, p.779-790

2024

Link zum Volltext

Verfügbarkeit prüfen

The antibody‐based delivery of interleukin‐12 to solid tumors boosts NK and CD8+ T cell activity and synergizes with immune checkpoint inhibitors

International journal of cancer, 2020-05, Vol.146 (9), p.2518-2530

2020

Link zum Volltext

Verfügbarkeit prüfen

Cross-reactivity to glutamate carboxypeptidase III causes undesired salivary gland and kidney uptake of PSMA-targeted small-molecule radionuclide therapeutics

European journal of nuclear medicine and molecular imaging, 2023-02, Vol.50 (3), p.957-961

2023

Link zum Volltext

Verfügbarkeit prüfen

A novel anti-cancer L19-interleukin-12 fusion protein with an optimized peptide linker efficiently localizes in vivo at the site of tumors

Journal of biotechnology, 2019-02, Vol.291, p.17-25

2019

Link zum Volltext

Verfügbarkeit prüfen

Impact of library input on the hit discovery rate in DNA-encoded chemical library selections

Chemical science (Cambridge), 2023-11, Vol.14 (43), p.1226-1233

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 53

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(52)
Mit Volltextzugriff
(49)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Chemically Defined Antibody– and Small Molecule–Drug Conjugates for in Vivo Tumor Targeting Applications: A Comparative Analysis

Versatile protein recognition by the encoded display of multiple chemical elements on a constant macrocyclic scaffold

Enhanced Therapeutic Activity of Non-Internalizing Small-Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX in Combination with Targeted Interleukin-2

An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications

Protease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody–Drug Conjugates

Stereo- and regiodefined DNA-encoded chemical libraries enable efficient tumour-targeting applications

An Attenuated Targeted-TNF Localizes to Tumors In Vivo and Regains Activity at the Site of Disease

Targeted Delivery of Cytotoxic Drugs: Challenges, Opportunities and New Developments

Ex vivo mass spectrometry-based biodistribution analysis of an antibody-Resiquimod conjugate bearing a protease-cleavable and acid-labile linker

Automated Radiosynthesis, Preliminary In Vitro/In Vivo Characterization of OncoFAP-Based Radiopharmaceuticals for Cancer Imaging and Therapy

Sortase-Mediated Site-Specific Modification of Interleukin‑2 for the Generation of a Tumor-Targeting Acetazolamide–Cytokine Conjugate

Deep Learning Approach for the Discovery of Tumor-Targeting Small Organic Ligands from DNA-Encoded Chemical Libraries

In Vivo Antitumor Activity of a Novel Acetazolamide–Cryptophycin Conjugate for the Treatment of Renal Cell Carcinomas

Acetazolamide Serves as Selective Delivery Vehicle for Dipeptide-Linked Drugs to Renal Cell Carcinoma

Linker stability influences the anti-tumor activity of acetazolamide-drug conjugates for the therapy of renal cell carcinoma

In Vivo Antitumor Activity of a Novel Acetazolamide–Cryptophycin Conjugate for the Treatment of Renal Cell Carcinoma

A Dimeric FAP-Targeting Small-Molecule Radioconjugate with High and Prolonged Tumor Uptake

Mass Spectrometry-Based Method for the Determination of the Biodistribution of Tumor-Targeting Small Molecule–Metal Conjugates

Targeted interleukin-2 enhances the in vivo anti-cancer activity of Pluvicto

Response to: GCP III is not the “off-target” for urea-based PSMA-ligands

In vivo activation of FAP-cleavable small molecule-drug conjugates for the targeted delivery of camptothecins and tubulin poisons to the tumor microenvironment

The antibody‐based delivery of interleukin‐12 to solid tumors boosts NK and CD8+ T cell activity and synergizes with immune checkpoint inhibitors

Cross-reactivity to glutamate carboxypeptidase III causes undesired salivary gland and kidney uptake of PSMA-targeted small-molecule radionuclide therapeutics

A novel anti-cancer L19-interleukin-12 fusion protein with an optimized peptide linker efficiently localizes in vivo at the site of tumors

Impact of library input on the hit discovery rate in DNA-encoded chemical library selections

Suchergebnisse filtern